Table 1 Demographic data of HD patients and control subjects.
HD (n = 20) | Control (n = 20) | P value | |
|---|---|---|---|
Age (years) | 67.4 ± 9.6 | 66.3 ± 9.1 | 0.71 |
Male (n, %) | 16 (80%) | 17 (85%) | 0.68 |
BMI (kg/m2) | 23.4 ± 3.8 | 23.7 ± 2.3 | 0.73 |
BSA (m2) | 1.7 ± 0.2 | 1.7 ± 0.2 | 0.44 |
Dialysis vintage (months) | 124.2 (48–156) | – | |
Hematocrit* (%) | 33.4 ± 5.0 | 41.0 ± 3.9 | < 0.0001 |
SBP* (mmHg) | 141.7 ± 20.8 | 141.3 ± 14.2 | 0.94 |
DBP (mmHg) | 68.3 ± 15.7 | 75.0 ± 8.4 | 0.10 |
HR (beats/min) | 68.5 ± 10.6 | 63.3 ± 7.7 | 0.09 |
eGFR (ml/min/1.73 m2) | – | 71.7 ± 15.6 | |
Medical and drug history | |||
Hypertension (n, %) | 18 (90%) | 16 (80%) | 0.38 |
Diabetes (n, %) | 11 (55%) | 10 (50%) | 0.75 |
Dyslipidemia (n, %) | 9 (45%) | 11 (55%) | 0.53 |
History of CAD (n, %) | 7 (35%) | 8 (40%) | 0.74 |
History of MI (n, %) | 3 (15%) | 4 (20%) | 0.63 |
ACEi/ARB (n, %) | 9 (45%) | 8 (40%) | 0.75 |
Calcium channel blocker (n, %) | 12 (60%) | 10 (50%) | 0.53 |
Alpha-blocker (n, %) | 1 (5%) | 1 (5%) | 1.00 |
Beta-blocker (n, %) | 9 (45%) | 5 (20%) | 0.19 |
Diuretic (n, %) | 3 (15%) | 3 (15%) | 1.00 |
Statin (n, %) | 7 (35%) | 11 (55%) | 0.20 |
Antiplatelet (n, %) | 16 (80%) | 13 (65%) | 0.29 |
Antidiabetic drugs (n, %) | 4 (20%) | 7 (35%) | 0.29 |
Insulin (n, %) | 4 (20%) | 2 (10%) | 0.38 |
Erythropoietin (n, %) | 20 (100%) | – | |
Etiology of renal disease | |||
Diabetic nephropathy (n, %) | 10 (50%) | ||
Nephrosclerosis (n, %) | 6 (30%) | ||
Glomerulonephritis (n, %) | 2 (10%) | ||
Polycystic kidney disease (n, %) | 1 (5%) | ||
Cholesterol crystal embolism (n, %) | 1 (5%) | ||
Propensity score | 0.129 ± 0.103 | 0.120 ± 0.106 | 0.78 |
